Clinical trial · Interventional
Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Intensive Induction for Newly Diagnosed Acute Myelogenous Leukemia
NCT00274807CI-TRIAL-00004407completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy, such as mitoxantrone, cytarabine, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating patients with newly diagnosed acute myeloid leukemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cytarabine | Drug | Cytarabine | ALIAS |
| etoposide | Drug | Etoposide | ALIAS |
| filgrastim | Biological | Filgrastim | ALIAS |
| mitoxantrone hydrochloride | Drug | Mitoxantrone | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Diagnosis of acute myeloid leukemia
* Previously untreated disease
* Previous hydroxyurea and/or corticosteroids are acceptable
* No preexisting history of a hematologic disorder
* Myelodysplastic features allowed
* No acute leukemia secondary to previous therapy
* No leukemic meningitis
PATIENT CHARACTERISTICS:
* Bilirubin \< 2.0 mg/dL (unless felt to be increased because of hepatic infiltration with leukemia)
* Creatinine \< 2.0 mg/dL
* Pregnant or lactating patients are ineligible
* Fertile patients must use effective contraception
* No history of or active congestive heart failure
PRIOR CONCURRENT THERAPY:
* See Disease CharacteristicsReferences
Publications (0)
Data not yet available
No reference posted for this study.